Communiqués de presse Archive - Page 23 of 23 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

2015 Annual Results in Line with Forecasts, and Significant Clinical Advances

First patients enrolled and dosed in the pivotal trial of Phase 3 of Tedopi®

OSE Pharma Announces U.S. Initiation of Atalante 1 in NSCLC

OSE Pharma Announces Initiation of its Pivotal Phase 3 trial of Tedopi® in NSCLC

OSE Pharma announces its events for Q1 2016

Précédent
1
…
20
21
22
23